Study of Total Body Irradiation in Combination With Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation Followed By Cyclosporine and Mycophenolate Mofetil in High Risk-Patients With Human Immunodeficiency Virus-1 - Full Text View

Purpose

OBJECTIVES:

I. Determine the safety of total body irradiation and post-transplant cyclosporine and mycophenolate mofetil in high-risk patients with human immunodeficiency virus-1.

II. Determine whether this regimen results in stable mixed donor lymphocyte chimerism (5-95% donor CD3) in this patient population.

III. Determine the kinetics of immune reconstruction following this treatment regimen in this patient population.

IV. Determine the effect of this treatment regimen on viral load in this patient population.

Condition	Intervention	Phase
HIV Infections	Drug: Cyclosporine Drug: Mycophenolate mofetil Procedure: Total body irradiation and stem cell or bone marrow transplantation	Phase II

MedlinePlus related topics:

AIDS Bone Marrow Transplantation

ChemIDplus related topics:

Cyclosporine Cyclosporin Mycophenolate Mofetil Mycophenolate mofetil hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label, Single Group Assignment, Safety Study

Official Title:	Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected With Human Immunodeficiency Virus-1 Using a Non-Marrow Ablative Conditioning Regimen Containing Total Body Irradiation in Combination With Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil

Further study details as provided by Office of Rare Diseases (ORD):

Primary Outcome Measures:

Mortality due to infection, donor chimerism [ Time Frame: Days 14, 28, 56, 80, 180, and 360 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

CD4, viral load [ Time Frame: Days 14, 28, 56, 80, 180, and 360 ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	20
Study Start Date:	November 2000
Estimated Study Completion Date:	December 2015
Estimated Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)

Arms

Assigned Interventions

1: Experimental

Participants will receive a stem cell transplantation along with a non-marrow ablative conditioning regimen containing total bdoy irradiation combined with post-transplant immunosuppression with cyclosporine and mycophenolate mofetil

Drug: Cyclosporine

Oral or IV cyclosporine 2 to 3 times daily on Days -1 to 50

Drug: Mycophenolate mofetil

Beginning within 6 hours of transplantation, oral mycophenolate mofetil every 12 hours until Day 27.

Procedure: Total body irradiation and stem cell or bone marrow transplantation

Assuming donor is available, total body irradiation followed by allogeneic peripheral blood stem cell or bone marrow transplantation on Day 0.

Detailed Description:

PROTOCOL OUTLINE:

Patients receive oral or IV cyclosporine 2-3 times daily on Days -1 to 50. Patients undergo total body irradiation followed by allogeneic peripheral blood stem cell or bone marrow transplantation on Day 0 (assuming donor is available). Beginning within 6 hours of transplantation, patients receive oral mycophenolate mofetil every 12 hours until Day 27.

Patients with an unstable level of chimerism may receive 1-2 donor lymphocyte infusions.

Patients are followed at Days 14, 28, 56, 80, 180, and 360.

Eligibility

Ages Eligible for Study:	up to 64 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Diagnosis of human immunodeficiency virus-1 not responsive to highly active antiretroviral therapy (HAART); treated with HAART for at least the past 6 months; viral load less than 50 copies/mL plasma; CD4 count less than 100/mm3
Lymphoma or other HIV-associated malignancy allowed with the following criteria: malignancy is in complete remission or very good partial remission, defined as a significant reduction of disease with therapy and no evidence of continued tumor growth; viral load has decreased by at least 1.5 logs OR to less than 5,000 copies/mL plasma while on HAART; CD4 count is allowed to be greater than 100/mm3
HLA genotypically identical donor available (under 75 years of age)

--Prior/Concurrent Therapy--

No concurrent growth factors during mycophenolate mofetil administration; concurrent continuation of anti-retroviral therapy required

--Patient Characteristics--

Life expectancy: At least 30 days
Other: No positive serology for Toxoplasma gondii; no other disease or organ dysfunction that would preclude survival; not pregnant or nursing; fertile patients must use effective contraception during and for 1 year after study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00010348

Locations


United States, Washington
	Fred Hutchinson Cancer Research Center	Recruiting
	Seattle, Washington, United States, 98109
	Contact: Ann Woolfrey 206-667-4453

Sponsors and Collaborators

Fred Hutchinson Cancer Research Center

Investigators


Study Chair:	Ann Woolfrey	Fred Hutchinson Cancer Research Center

More Information

Responsible Party:	Fred Hutchinson Cancer Research Center ( Ann Woolfrey / Associate in Clinical Research )
Study ID Numbers:	199/15576, FHCRC-1410.00
First Received:	February 2, 2001
Last Updated:	September 2, 2008
ClinicalTrials.gov Identifier:	NCT00010348
Health Authority:	United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):

human immunodeficiency virus infection

immunologic disorders and infectious disorders

rare disease

viral infection

Study placed in the following topic categories:

Sexually Transmitted Diseases, Viral

Cyclosporine

Clotrimazole

Miconazole

Acquired Immunodeficiency Syndrome

Tioconazole

Rare Diseases

Mycophenolic Acid

Cyclosporins

Immunologic Deficiency Syndromes

Virus Diseases

HIV Infections

Sexually Transmitted Diseases

Mycophenolate mofetil

Retroviridae Infections

Additional relevant MeSH terms:

Anti-Infective Agents

RNA Virus Infections

Slow Virus Diseases

Immunologic Factors

Immune System Diseases

Molecular Mechanisms of Pharmacological Action

Antineoplastic Agents

Physiological Effects of Drugs

Enzyme Inhibitors

Antibiotics, Antineoplastic

Infection

Immunosuppressive Agents

Pharmacologic Actions

Antifungal Agents

Therapeutic Uses

Lentivirus Infections

Antirheumatic Agents

Dermatologic Agents

ClinicalTrials.gov processed this record on September 05, 2008

Sponsored by:	Fred Hutchinson Cancer Research Center
Information provided by:	Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:	NCT00010348